Biotech Startups

Orange Grove Bio is a biotech venture firm that builds and backs cell therapy and immuno-oncology companies, forming subsidiary companies (subcos) such as Ipinovyx and DomainOne Therapeutics. It operates in the biopharmaceutical and life sciences investment space.

1 investor

Orbicle Bio develops carbon-negative organic fertilizers made from naturally-derived microbes and their nutrients to promote crop growth and reduce reliance on synthetic fertilizers. The company targets the agriculture market and expects its first product to be commercially available in 2025/2026.

1 investor

OrbiMed is a global investment firm that manages public equity, private equity, and private credit/royalty strategies focused on the healthcare industry.

1 investor

Orbion provides a computational platform for protein engineering that characterizes sequences, ranks stabilizing mutations, predicts construct expression, and generates experimental protocols to filter designs before lab synthesis. The platform serves biotechnology researchers and protein engineers working to optimize protein candidates for expression and function.

1 investor

Orbis Medicines is a drug discovery company developing orally bioavailable macrocycle drug candidates as alternatives to injectable biologics, targeting both intracellular and extracellular protein targets. It uses a proprietary chemistry and machine-learning platform to systematically explore macrocycle chemical space and generate optimized drug candidates.

1 investor

Orbit works on complex problems in neuroscience.

1 investor

Orchestra BioMed develops medical device products and uses a partnership-based model, collaborating with medical device companies to commercialize them globally. It operates in the medical device and biomedical industry.

1 investor

Orchidia is a pharmaceutical company that completed a third investment round in 2026 with strategic international investors including SPE Capital, Proparco, EBRD, and BIO.

1 investor

Orenitram is a prescription oral medication containing treprostinil, indicated to treat pulmonary arterial hypertension (PAH) by slowing disease progression and improving exercise capacity in adults. The site is a drug information page covering safety, dosing, and side-effect details for patients and healthcare providers.

1 investor

Organ Recovery Systems develops organ preservation products and services, including machine perfusion technology for donor kidneys, for transplant programs and transplant professionals. The company supports over 400 transplant programs across 49 countries and also provides clinical and technical support services.

1 investor

Organo-ID develops iPSC-derived organoid systems, including 3D hepatocyte models, to test drugs in better-modeled biological systems for predictive diagnostics and personalized therapies. The company serves drug development and treatment applications in oncology and rare disease, operating from Turkey with a global focus.

1 investor

Organogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.

1 investor

ORIA is a Paris-based company, spun off from ENS Paris in 2022, that uses a proprietary mechanical microfluidic platform to extract intact, high-purity functional organelles at industrial scale. Its organelle products serve pharmaceutical companies, biotech firms, and academic institutions for drug discovery, disease modeling, and therapeutic research.

1 investor

Origami Therapeutics is a preclinical-stage biopharmaceutical company developing protein degrader therapeutics to treat neurodegenerative diseases, starting with Huntington's disease. The company uses a proprietary platform that harnesses the body's natural protein disposal system to degrade disease-causing proteins.

1 investor

OriGene supplies research reagents including primary antibodies for flow cytometry, transfection kits (EZ-LNP and ProteanFect), RNAi gene silencing tools, and control solutions for life science laboratories. Its products serve researchers in molecular and cell biology.

1 investor

Origin by Ocean harvests invasive algae blooms to create bio-based ingredients for cosmetics, food, and textile industries through a proprietary biorefining process. The company addresses ocean pollution and ecosystem degradation while producing sustainable, regenerative materials.

1 investor

Origin Endoscopy has developed a multipurpose hydrogel designed for rapid bio-adhesion and submucosal injection applications in endoscopy. The technology targets surgical and medical procedure workflows that require biocompatible materials.

1 investor

Origin Sciences applies a hologenomic approach integrating host genetics, epigenetics, and microbiome analysis into a single diagnostic framework for deeper health assessment. The company works with leading institutions and technology providers to develop and scale advanced diagnostic assays for clinical and research applications.

1 investor

Pareon Biosystems has developed a multiplex biomarker quantification method that produces absolute measurements with built-in correction for non-specific binding. The approach uses low concentrations of common reagents and standard lab equipment such as PCR, targeting personalized/precision medicine applications in research and clinical settings, including resource-limited environments.

1 investor

Orio Therapeutics develops protein-based therapeutics using a technology that modifies therapeutic proteins with a built-in delivery system to control their localization at the injection site, improving efficacy and reducing dosage in regenerative medicine. Its first application is a molecule to protect cardiac muscle following a heart attack (myocardial infarction) by reducing fibrosis and cellular death.

1 investor

Orogen Therapeutics uses AI and machine learning to accelerate drug discovery, focusing on small molecule candidates for immuno-inflammatory diseases. The company combines computational chemistry, DNA-encoded library technology, and medicinal expertise to develop novel therapeutic medicines.

1 investor

Orphalan develops and commercializes innovative therapies for patients with rare diseases, with a focus on unmet medical needs where current treatments are limited or absent. The company has successfully brought trientine tetrahydrochloride (Cuprior®/Cuvrior®) to market for Wilson disease treatment across 30+ countries.

1 investor

Ortho BioMed combines expertise in medicine, engineering, and data science to develop medical technology solutions that improve patient outcomes.

1 investor

OrthoPreserve develops a minimally invasive meniscus implant for orthopedic care, designed to address unmet clinical needs in knee surgery. The company is co-founded by orthopedic clinicians and engineers with expertise across R&D, manufacturing, regulatory compliance, and surgical practice.

1 investor